Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy

Eleonora Dondossola, Angelo Corti, Richard L. Sidman, Wadih Arap, Renata Pasqualini

Research output: Contribution to journalArticle

Abstract

Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b+CD13+ myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b+CD13+ myeloid cells could become a non-malignant target for the development of novel anticancer regimens.

Original languageEnglish
Article numbere27716
JournalOncoImmunology
Volume3
Issue number1
DOIs
Publication statusPublished - 2014

Keywords

  • Angiogenesis
  • Bone marrow-derived cells
  • CD13
  • Mouse models
  • Tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy'. Together they form a unique fingerprint.

  • Cite this